D. E. Shaw & Co. Inc. Decreases Holdings in Quanterix Co. (NASDAQ:QTRX)

D. E. Shaw & Co. Inc. lessened its stake in Quanterix Co. (NASDAQ:QTRX - Free Report) by 56.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 82,192 shares of the company's stock after selling 106,200 shares during the period. D. E. Shaw & Co. Inc. owned about 0.21% of Quanterix worth $874,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Resona Asset Management Co. Ltd. acquired a new stake in shares of Quanterix in the fourth quarter valued at $55,000. Tower Research Capital LLC TRC grew its position in Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after acquiring an additional 3,915 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Quanterix during the fourth quarter worth about $66,000. Canada Pension Plan Investment Board lifted its position in shares of Quanterix by 64.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock worth $108,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new stake in shares of Quanterix during the fourth quarter worth about $108,000. Hedge funds and other institutional investors own 86.48% of the company's stock.

Quanterix Price Performance

Shares of Quanterix stock traded down $0.04 during trading on Thursday, hitting $5.24. 397,791 shares of the stock were exchanged, compared to its average volume of 575,235. The firm's 50-day moving average price is $5.48 and its 200 day moving average price is $8.25. The stock has a market cap of $203.46 million, a price-to-earnings ratio of -4.94 and a beta of 1.12. Quanterix Co. has a 12-month low of $4.05 and a 12-month high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.16. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. As a group, research analysts forecast that Quanterix Co. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on QTRX. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Leerink Partnrs downgraded shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Canaccord Genuity Group reduced their price objective on Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen lowered Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Leerink Partners restated a "market perform" rating and set a $8.00 price target (down previously from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $15.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.